JAK

Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.

Cat.No. 产品名称 Information
GC25992 TG-89 TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
GC25869 RO495 RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
GC25168 Brepocitinib (PF-06700841) Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
GC67867 VVD-118313
GC66329 NDI-034858
GC65453 JAK-IN-3
GC65405 JAK2-IN-6
GC65387 Tyk2-IN-5
GC64959 JAK/HDAC-IN-1
GC64701 Povorcitinib
GC64700 Povorcitinib phosphate
GC64372 Lorpucitinib
GC64108 Ifidancitinib
GC63864 (E/Z)-Zotiraciclib hydrochloride
GC49692 Tofacitinib-d3 (citrate) An internal standard for the quantification of tofacitinib
GC63448 JAK-IN-14
GC63416 Itacnosertib
GC63309 Ilunocitinib
GC63029 JAK1-IN-8
GC62908 Coumermycin A1
GC62665 JAK2/FLT3-IN-1 TFA
GC62500 JAK2-IN-7
GC62491 BMS-986202
GC62313 Izencitinib
GC62246 G5-7 G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2.
GC62233 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide A TYK2 inhibitor
GC62130 (2R,5S)-Ritlecitinib
GC62112 Zotiraciclib Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.
GC61807 (E/Z)-AG490
GC47450 IL-4 Inhibitor An IL-4 inhibitor
GC46503 2-(1,8-Naphthyridin-2-yl)phenol An enhancer of STAT1 activity
GC50480 PF 06651600 malonate Potent and selective JAK3 inhibitor
GC50066 Atiprimod dihydrochloride JAK2 inhibitor
GC46148 Filgotinib-d4 An internal standard for the quantification of filgotinib
GC39081 Reticuline
GC37971 ZM39923 A potent inhibitor of JAK3
GC37847 Tyk2-IN-8 Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
GC37846 Tyk2-IN-7
GC37575 Ruxolitinib sulfate A potent, selective JAK1/JAK2 inhibitor
GC37523 RGB-286638 free base A multi-kinase inhibitor
GC37522 RGB-286638 A multi-kinase inhibitor
GC36882 PF-06263276
GC36783 NVP-BSK805 dihydrochloride A potent, selective JAK2 inhibitor
GC36646 Momelotinib Mesylate
GC36366 JAK-IN-10
GC36365 JAK3 covalent inhibitor-1
GC36364 JAK2-IN-4
GC36363 JAK1-IN-7
GC36351 Itacitinib adipate A JAK1 inhibitor
GC35554 Brevilin A A sesquiterpene lactone with anticancer activity